Breaking News Instant updates and real-time market news.

NDX

Nasdaq 100 Index

/

+

08:20
06/11/21
06/11
08:20
06/11/21
08:20

Nasdaq 100 Index: Pivot points

The following are the pivot points for the Nasdaq 100 Index (NDX). Pivot High: 14034.24, Pivot Low: 13889.09. These were calculated using the DeMark method. It is generally believed to be bullish when price breaks out above the pivot high or bearish when price breaks down below the pivot low.

TODAY'S FREE FLY STORIES

General news
FX Action: USD-CAD has remained buoyed » 04:00
06/14/21
06/14
04:00
06/14/21
04:00
$ECON

Economic Data

/

+

FX Action: USD-CAD has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

General news
FX Update: The dollar has remained firmer » 03:30
06/14/21
06/14
03:30
06/14/21
03:30
$ECON

Economic Data

/

+

FX Update: The dollar has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

General news
Asian Market Update: » 03:05
06/14/21
06/14
03:05
06/14/21
03:05
$ECON

Economic Data

/

+

Asian Market Update: It…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

General news
FOMC Forecast revisions » 03:05
06/14/21
06/14
03:05
06/14/21
03:05
$ECON

Economic Data

/

+

FOMC Forecast revisions,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

General news
The FOMC headlines this week with the meeting on June 15-16. » 03:05
06/14/21
06/14
03:05
06/14/21
03:05
$ECON

Economic Data

/

+

The FOMC headlines this…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

Periodicals
Washington Prime to file bankruptcy as soon as this week, Reuters reports » 21:31
06/13/21
06/13
21:31
06/13/21
21:31
WPG

Washington Prime

$4.84 /

-0.26 (-5.10%)

Mall owner Washington…

Mall owner Washington Prime Group is preparing to seek bankruptcy protection as soon as this week after the COVID-19 pandemic forced it to temporarily close some of its roughly 100 shopping centers across the United States and businesses were unable to pay it rent, Reuters' Mike Spector reports, citing people familiar with the matter. Reference Link

ShowHide Related Items >><<
WPG Washington Prime
$4.84 /

-0.26 (-5.10%)

WPG Washington Prime
$4.84 /

-0.26 (-5.10%)

04/06/21 Truist
Washington Prime upgraded to Hold from Sell at Truist
04/05/21 Truist
Washington Prime upgraded to Hold from Sell at Truist
02/16/21 Truist
Washington Prime coupon non-payment part of negotiating process, says Truist
02/01/21 Truist
Macerich Q4 results 'weak,' but not much worse than expected, says Truist
WPG Washington Prime
$4.84 /

-0.26 (-5.10%)

WPG Washington Prime
$4.84 /

-0.26 (-5.10%)

WPG Washington Prime
$4.84 /

-0.26 (-5.10%)

Periodicals
Shell weighs sale of Texas shale assets, Reuters reports » 21:29
06/13/21
06/13
21:29
06/13/21
21:29
RDS.A

Royal Dutch Shell

$40.42 /

+0.32 (+0.80%)

, RDS.B

Royal Dutch Shell

$38.25 /

+0.425 (+1.12%)

Royal Dutch Shell is…

Royal Dutch Shell is reviewing its holdings in the largest U.S. oil field for a potential sale, marking a key moment in its shift away from fossil fuels as it faces growing pressure to slash carbon emissions, Reuters' Ron Bousso, Jessica Resnick-Ault and David French report, citing people familiar with the matter. The sale could be for part or all of Shell's position in the U.S. Permian Basin, located mostly in Texas, which accounted for around 6% of the Anglo-Dutch company's total oil and gas output last year, the authors note. The holdings could be worth more than $10 billion, the people said. Reference Link

ShowHide Related Items >><<
RDS.B Royal Dutch Shell
$38.25 /

+0.425 (+1.12%)

RDS.A Royal Dutch Shell
$40.42 /

+0.32 (+0.80%)

RDS.A Royal Dutch Shell
$40.42 /

+0.32 (+0.80%)

06/08/21 DZ Bank
Royal Dutch Shell downgraded to Hold from Buy at DZ Bank
05/17/21 Mizuho
Royal Dutch Shell price target raised to $61 from $56 at Mizuho
04/30/21 Credit Suisse
Royal Dutch Shell price target raised to 1,860 GBp at Credit Suisse
04/20/21 Deutsche Bank
Royal Dutch Shell initiated with a Buy at Deutsche Bank
RDS.B Royal Dutch Shell
$38.25 /

+0.425 (+1.12%)

04/08/21 Barclays
Royal Dutch Shell price target raised to 1,700 GBp from 1,500 GBp at Barclays
03/12/21 Societe Generale
Royal Dutch Shell upgraded to Buy from Hold at Societe Generale
03/03/21 JPMorgan
Royal Dutch Shell price target raised to 2,000 GBp from 1,700 GBp at JPMorgan
02/12/21 Scotiabank
Royal Dutch Shell upgraded to Sector Perform from Underperform at Scotiabank
RDS.A Royal Dutch Shell
$40.42 /

+0.32 (+0.80%)

RDS.B Royal Dutch Shell
$38.25 /

+0.425 (+1.12%)

RDS.A Royal Dutch Shell
$40.42 /

+0.32 (+0.80%)

RDS.B Royal Dutch Shell
$38.25 /

+0.425 (+1.12%)

RDS.A Royal Dutch Shell
$40.42 /

+0.32 (+0.80%)

Recommendations
Vertex Pharmaceuticals price target lowered to $261 from $347 at Piper Sandler » 21:28
06/13/21
06/13
21:28
06/13/21
21:28
VRTX

Vertex Pharmaceuticals

$193.02 /

-23.93 (-11.03%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Vertex Pharmaceuticals to $261 from $347 and reiterates an Overweight rating on the shares. The stock traded down 11% Friday on discontinuation of VX-864 as investors looks for Vertex's next growth driver, Tenthoff tells investors in a research note.

ShowHide Related Items >><<
VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

06/11/21 Roth Capital
Crispr Therapeutics reported 'robust' sickle cell data, says Roth Capital
06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 Stifel
Vertex shares look 'cheap' at aftermarket levels, says Stifel
06/11/21 Cantor Fitzgerald
Vertex Pharmaceuticals price target lowered to $281 from $285 at Cantor Fitzgerald
VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

VRTX Vertex Pharmaceuticals
$193.02 /

-23.93 (-11.03%)

Hot Stocks
Fly Intel: Top five weekend stock stories » 20:14
06/13/21
06/13
20:14
06/13/21
20:14
AGC

Altimeter Growth

$11.74 /

+0.065 (+0.56%)

, TSLA

Tesla

$609.92 /

-0.16 (-0.03%)

, BIIB

Biogen

$396.46 /

-18.29 (-4.41%)

, LLY

Eli Lilly

$224.12 /

-9.42 (-4.03%)

, RHHBY

Roche

$47.56 /

-0.22 (-0.46%)

, VIAC

ViacomCBS

$42.36 /

+0.845 (+2.04%)

, VIACA

ViacomCBS

$46.64 /

+0.6 (+1.30%)

, UPS

UPS

$203.24 /

+0.065 (+0.03%)

, DOCU

DocuSign

$253.05 /

+9.9 (+4.07%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Grab Holdings CEO Anthony Tan said he's confident the merger of the ride-hailing and food-delivery giant and a U.S. blank-check company will be completed by year-end, following a delay caused by a review of its financials, Bloomberg's Yoolim Lee and Juliette Saly reported. The Singapore-based startup last week postponed the expected completion of the deal with Altimeter Growth Corp. (AGC) - set to be one of the largest-ever mergers with a special purpose acquisition company - to the fourth quarter as it works on an audit of the past three years, the authors noted. 2. Tesla's (TSLA) CEO Elon Musk said via Twitter that, " Tesla only sold ~10% of holdings to confirm BTC could be liquidated easily without moving market. When there's confirmation of reasonable (~50%) clean energy usage by miners with positive future trend, Tesla will resume allowing Bitcoin transactions." 3. When the U.S. Food and Drug Administration approved Aduhelm, Biogen's (BIIB) Alzheimer's disease therapy, this past Monday, it did so on the basis of the drug's ability to reduce the level of junk proteins in patients' brains, Josh Nathan-Kazis wrote in this week's edition of Barron's. The agency believes that clearing those proteins, called amyloid plaques, reduces cognitive decline, he added, noting that the move now opens the possibility of approvals for other drugs that, like Aduhelm, can clear amyloid plaque, but haven't been proven definitively to slow cognitive decline. Eli Lilly's (LLY) donanemab is one. Gantenerumab, from Roche Holding (RHHBY), is another. Biogen and its partner, Eisai (ESALY), have a third, known as BAN2401. 4. ViacomCBS (VIAC) subsidiary Paramount's "A Quiet Place II" won this weekend's box office with a surprising $11.7M for a domestic total of about $109M. The horror movie is the first in the pandemic era to cross the $100M mark domestically. 5. UPS (UPS) and DocuSign (DOCU) saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
VIACA ViacomCBS
$46.64 /

+0.6 (+1.30%)

VIAC ViacomCBS
$42.36 /

+0.845 (+2.04%)

UPS UPS
$203.24 /

+0.065 (+0.03%)

TSLA Tesla
$609.92 /

-0.16 (-0.03%)

RHHBY Roche
$47.56 /

-0.22 (-0.46%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

AGC Altimeter Growth
$11.74 /

+0.065 (+0.56%)

AGC Altimeter Growth
$11.74 /

+0.065 (+0.56%)

TSLA Tesla
$609.92 /

-0.16 (-0.03%)

06/11/21 Credit Suisse
Tesla's Model S Plaid reinforces brand DNA, says Credit Suisse
06/11/21 Goldman Sachs
Goldman says Tesla's Model S Plaid helps illustrate technology leadership
06/08/21 GLJ Research
Tesla's China orders down 69% in Q2 versus Q1, says GLJ Research
06/08/21 Wedbush
Tesla China numbers rebound in 'big way,' says Wedbush
BIIB Biogen
$396.46 /

-18.29 (-4.41%)

06/11/21
Fly Intel: Top five analyst upgrades
06/11/21 Bernstein
Biogen upgraded to Outperform from Market Perform at Bernstein
06/11/21 RBC Capital
Prothena price target raised to $50 from $28 at RBC Capital
06/11/21 Bernstein
Biogen upgraded to Outperform from Market Perform at Bernstein
LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

06/08/21 Baird
Baird upgrades Biogen to Neutral after 'fatal blow' to bear thesis
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
05/27/21 H.C. Wainwright
H.C. Wainwright bullish on Dicerna as new RNAi candidate enters clinic
05/24/21 H.C. Wainwright
Aurinia reported positive data as competitors 'stumble,' says H.C. Wainwright
RHHBY Roche
$47.56 /

-0.22 (-0.46%)

06/10/21 Morgan Stanley
Roche price target raised to CHF 370 from CHF 345 at Morgan Stanley
06/02/21 Societe Generale
Roche downgraded to Hold from Buy at Societe Generale
05/05/21 BTIG
Mereo BioPharma initiated with a Buy at BTIG
VIAC ViacomCBS
$42.36 /

+0.845 (+2.04%)

05/24/21 Truist
Lionsgate price target raised to $19 from $15 at Truist
05/21/21 Citi
ViacomCBS price target lowered to $54 from $56 at Citi
05/20/21
Fly Intel: Top five analyst upgrades
05/20/21 BofA
ViacomCBS upgraded to Buy from Underperform at BofA
VIACA ViacomCBS
$46.64 /

+0.6 (+1.30%)

01/05/21 Gabelli
ViacomCBS named a best idea for 2021 at Gabelli
07/13/20
Fly Intel: Top five analyst initiations
07/13/20
Fly Intel: Top five analyst downgrades
UPS UPS
$203.24 /

+0.065 (+0.03%)

06/10/21
Fly Intel: Top five analyst upgrades
06/10/21 BMO Capital
UPS price target raised to $200 from $195 at BMO Capital
06/10/21 Oppenheimer
UPS price target raised to $222 from $210 at Oppenheimer
06/10/21 Stephens
UPS event 'failed to live up to raised investor expectations,' says Stephens
DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

06/10/21 RBC Capital
DocuSign assumed with an Outperform at RBC Capital
06/04/21 Wedbush
DocuSign price target lowered to $260 from $300 at Wedbush
06/04/21 Morgan Stanley
DocuSign price target raised to $295 from $290 at Morgan Stanley
06/04/21 Oppenheimer
DocuSign price target lowered to $260 from $300 at Oppenheimer
VIAC ViacomCBS
$42.36 /

+0.845 (+2.04%)

UPS UPS
$203.24 /

+0.065 (+0.03%)

TSLA Tesla
$609.92 /

-0.16 (-0.03%)

RHHBY Roche
$47.56 /

-0.22 (-0.46%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

  • 06
    Apr
  • 29
    Mar
  • 24
    Mar
VIACA ViacomCBS
$46.64 /

+0.6 (+1.30%)

VIAC ViacomCBS
$42.36 /

+0.845 (+2.04%)

UPS UPS
$203.24 /

+0.065 (+0.03%)

TSLA Tesla
$609.92 /

-0.16 (-0.03%)

RHHBY Roche
$47.56 /

-0.22 (-0.46%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

AGC Altimeter Growth
$11.74 /

+0.065 (+0.56%)

VIAC ViacomCBS
$42.36 /

+0.845 (+2.04%)

UPS UPS
$203.24 /

+0.065 (+0.03%)

TSLA Tesla
$609.92 /

-0.16 (-0.03%)

RHHBY Roche
$47.56 /

-0.22 (-0.46%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

AGC Altimeter Growth
$11.74 /

+0.065 (+0.56%)

VIAC ViacomCBS
$42.36 /

+0.845 (+2.04%)

UPS UPS
$203.24 /

+0.065 (+0.03%)

TSLA Tesla
$609.92 /

-0.16 (-0.03%)

LLY Eli Lilly
$224.12 /

-9.42 (-4.03%)

DOCU DocuSign
$253.05 /

+9.9 (+4.07%)

BIIB Biogen
$396.46 /

-18.29 (-4.41%)

AGC Altimeter Growth
$11.74 /

+0.065 (+0.56%)

Periodicals
Grab CEO confident SPAC deal to close by year-end, Bloomberg reports » 20:08
06/13/21
06/13
20:08
06/13/21
20:08
AGC

Altimeter Growth

$11.74 /

+0.065 (+0.56%)

Grab Holdings CEO Anthony…

Grab Holdings CEO Anthony Tan said he's confident the merger of the ride-hailing and food-delivery giant and a U.S. blank-check company will be completed by year-end, following a delay caused by a review of its financials, Bloomberg's Yoolim Lee and Juliette Saly report. The Singapore-based startup last week postponed the expected completion of the deal with Altimeter Growth Corp. - set to be one of the largest-ever mergers with a special purpose acquisition company - to the fourth quarter as it works on an audit of the past three years, the authors note. Reference Link

ShowHide Related Items >><<
AGC Altimeter Growth
$11.74 /

+0.065 (+0.56%)

AGC Altimeter Growth
$11.74 /

+0.065 (+0.56%)

AGC Altimeter Growth
$11.74 /

+0.065 (+0.56%)

AGC Altimeter Growth
$11.74 /

+0.065 (+0.56%)

Downgrade
Ferrari downgraded to Sell from Buy at Goldman Sachs » 19:49
06/13/21
06/13
19:49
06/13/21
19:49
RACE

Ferrari

$211.19 /

-0.06 (-0.03%)

Goldman Sachs analyst…

Goldman Sachs analyst George Galliers downgraded Ferrari to Sell from Buy with a $207 price target. The analyst expects the broader auto industry to benefit over the next 12-18 months from a sequential improvement in global production, as a result of easing of semi-conductor shortages, improving end markets and the need to re-stock. However, he does not expect Ferrari to be a notable beneficiary of this development. Further, following the announcement of a BEV by 2025, and the appointment of a new CEO with a tech background, Galliers expects Ferrari to accelerate its transition to technologies of the future. While he would view this development as a positive for Ferrari's long-term future, the analyst believes it may drive the need for incremental capex.

ShowHide Related Items >><<
RACE Ferrari
$211.19 /

-0.06 (-0.03%)

RACE Ferrari
$211.19 /

-0.06 (-0.03%)

05/19/21 Redburn
Redburn downgrades Ferrari on free cash flow margin concerns
05/19/21 Redburn
Ferrari downgraded to Neutral from Buy at Redburn
05/06/21 RBC Capital
Ferrari price target lowered to EUR 202 from EUR 204 at RBC Capital
05/05/21
Fly Intel: Top five analyst downgrades
RACE Ferrari
$211.19 /

-0.06 (-0.03%)

Initiation
Hess Midstream Partners initiated with a Buy at Goldman Sachs » 19:28
06/13/21
06/13
19:28
06/13/21
19:28
HESM

Hess Midstream Partners

$25.99 /

+0.06 (+0.23%)

, HES

Hess Corp.

$89.69 /

+0.665 (+0.75%)

Goldman Sachs analyst…

Goldman Sachs analyst Michael Lapides initiated coverage of Hess Midstream Partners (HESM) with a Buy rating and $30 price target. The analyst cites a unique contract structure with its sponsor Hess (HES) that significantly reduces volumetric and pricing risk relative to peers, best in class leverage metrics and returns, and improving free cash flow that, along with strong credit metrics, could lead to a multi-year capital allocation story or could fund growth via drop downs. Lapides also sees upside to consensus EBITDA estimates on a mix of volume expectations, tariff rates, and cost management, and views Hess Midstream Partners as a premium story among small/mid cap stocks.

ShowHide Related Items >><<
HESM Hess Midstream Partners
$25.99 /

+0.06 (+0.23%)

HES Hess Corp.
$89.69 /

+0.665 (+0.75%)

HESM Hess Midstream Partners
$25.99 /

+0.06 (+0.23%)

02/01/21 Scotiabank
Hess Midstream Partners resumed with an Outperform at Scotiabank
12/17/20 Credit Suisse
Hess Midstream Partners downgraded to Neutral from Outperform at Credit Suisse
12/11/20 Morgan Stanley
Morgan Stanley upgrades midstream industry view to Attractive, shakes up ratings
12/11/20 Morgan Stanley
Hess Midstream upgraded to Overweight from Equal Weight at Morgan Stanley
HES Hess Corp.
$89.69 /

+0.665 (+0.75%)

06/11/21 JPMorgan
Hess Corp. price target raised to $100 from $80 at JPMorgan
06/09/21 Goldman Sachs
Goldman Sachs keeps Buy on Hess, Exxon Mobil after successful Longtail appraisal
06/03/21 Barclays
Hess Corp. price target raised to $91 from $81 at Barclays
06/01/21 Wells Fargo
Hess Corp. price target raised to $98 from $86 at Wells Fargo
HESM Hess Midstream Partners
$25.99 /

+0.06 (+0.23%)

HES Hess Corp.
$89.69 /

+0.665 (+0.75%)

  • 11
    Mar
HESM Hess Midstream Partners
$25.99 /

+0.06 (+0.23%)

HES Hess Corp.
$89.69 /

+0.665 (+0.75%)

Downgrade
Kinder Morgan downgraded to Sell from Neutral at Goldman Sachs » 19:25
06/13/21
06/13
19:25
06/13/21
19:25
KMI

Kinder Morgan

$19.14 /

+0.15 (+0.79%)

Goldman Sachs analyst…

Goldman Sachs analyst Michael Lapides downgraded Kinder Morgan to Sell from Neutral on valuation as he expects shares to lag large-cap midstream peers in the second half of 2021 with more upside elsewhere in his coverage. The analyst notes Kinder's shares are up 39% year-to-date compared to large-cap peers up 38% and the AMNA index up 41%, which he attributes to an improving outlook for refined products demand as well as the broader value rotation. However, Lapides believes Kinder has outpaced a "reasonable" valuation level relative to its peers.

ShowHide Related Items >><<
KMI Kinder Morgan
$19.14 /

+0.15 (+0.79%)

KMI Kinder Morgan
$19.14 /

+0.15 (+0.79%)

06/04/21 Mizuho
Kinder Morgan price target raised to $21 from $20 at Mizuho
05/26/21 Morgan Stanley
Kinder Morgan cut to Underweight at Morgan Stanley on lack of relative upside
05/26/21 Morgan Stanley
Kinder Morgan downgraded to Underweight from Equal Weight at Morgan Stanley
05/13/21 Wells Fargo
Kinder Morgan downgraded to Underweight from Equal Weight at Wells Fargo
KMI Kinder Morgan
$19.14 /

+0.15 (+0.79%)

KMI Kinder Morgan
$19.14 /

+0.15 (+0.79%)

KMI Kinder Morgan
$19.14 /

+0.15 (+0.79%)

KMI Kinder Morgan
$19.14 /

+0.15 (+0.79%)

Upgrade
Cheniere Energy Partners upgraded to Buy from Neutral at Goldman Sachs » 19:22
06/13/21
06/13
19:22
06/13/21
19:22
CQP

Cheniere Energy Partners

$43.10 /

+0.13 (+0.30%)

Goldman Sachs analyst…

Goldman Sachs analyst Michael Lapides upgraded Cheniere Energy Partners to Buy from Neutral with a $56 price target. The analyst cites recent underperformance, its defensive and largely contracted asset base that offers visibility into stable cash flows and upside to consensus from tailwinds to Cheniere Energy Partners' commodity margins from global natural gas prices.

ShowHide Related Items >><<
CQP Cheniere Energy Partners
$43.10 /

+0.13 (+0.30%)

CQP Cheniere Energy Partners
$43.10 /

+0.13 (+0.30%)

03/12/21
Fly Intel: Top five analyst downgrades
03/12/21 JPMorgan
Cheniere Energy Partners downgraded to Underweight from Neutral at JPMorgan
02/01/21 Scotiabank
Cheniere Energy Partners downgraded to Sector Perform from Outperform at Scotiabank
12/03/20 SMBC Nikko
Cheniere Energy Partners initiated with a Neutral at SMBC Nikko
CQP Cheniere Energy Partners
$43.10 /

+0.13 (+0.30%)

CQP Cheniere Energy Partners
$43.10 /

+0.13 (+0.30%)

Periodicals
EMA says AstraZeneca shots have good risk-benefit for over 60s, Reuters says » 18:01
06/13/21
06/13
18:01
06/13/21
18:01
AZN

AstraZeneca

$58.77 /

-0.08 (-0.14%)

The head of the EU drug…

The head of the EU drug regulator's COVID-19 task force said on Sunday that AstraZeneca's coronavirus vaccine had a favorable risk-benefit profile for all age groups and particularly for those aged over 60, according to Reuters. Reference Link

ShowHide Related Items >><<
AZN AstraZeneca
$58.77 /

-0.08 (-0.14%)

AZN AstraZeneca
$58.77 /

-0.08 (-0.14%)

06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
AZN AstraZeneca
$58.77 /

-0.08 (-0.14%)

AZN AstraZeneca
$58.77 /

-0.08 (-0.14%)

AZN AstraZeneca
$58.77 /

-0.08 (-0.14%)

AZN AstraZeneca
$58.77 /

-0.08 (-0.14%)

Periodicals
Microsoft promises Halo Infinite for holiday season, Bloomberg reports » 17:56
06/13/21
06/13
17:56
06/13/21
17:56
MSFT

Microsoft

$257.88 /

+0.64 (+0.25%)

Microsoft said during a…

Microsoft said during a press showcase at the E3 gaming conference that its much-anticipated Halo Infinite will be out this holiday season, Bloomberg's Jason Schreier and Dina Bass report. The newest Halo will feature a standard single-player campaign mode and a multiplayer component that will be free to all players, even if they don't buy the game, Microsoft said. The presentation was brief and showed minimal gameplay from the campaign, the authors note. Reference Link

ShowHide Related Items >><<
MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

06/07/21 Morgan Stanley
Microsoft valuation presents 'attractive entry point,' says Morgan Stanley
06/03/21 Tigress Financial
Microsoft shares going to $303 in 12 months, says Tigress Financial
06/01/21 KGI Securities
Microsoft initiated with an Outperform at KGI Securities
05/27/21 UBS
Zoom Video initiated with a Neutral at UBS
MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

On The Fly
Box Office Battle: 'In the Heights' loses to 'A Quiet Place II' » 17:53
06/13/21
06/13
17:53
06/13/21
17:53
T

AT&T

$29.33 /

+0.15 (+0.51%)

, CMCSA

Comcast

$56.88 /

+0.29 (+0.51%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, SONY

Sony

$99.64 /

+0.915 (+0.93%)

, LGF.A

Lionsgate

$20.28 /

-0.11 (-0.54%)

, LGF.B

Lionsgate

$17.85 /

-0.2 (-1.11%)

, DIS

Disney

$177.36 /

+0.81 (+0.46%)

, VIACA

ViacomCBS

$46.64 /

+0.6 (+1.30%)

, VIAC

ViacomCBS

$42.36 /

+0.845 (+2.04%)

"Box Office Battle" is…

ShowHide Related Items >><<
VIACA ViacomCBS
$46.64 /

+0.6 (+1.30%)

VIAC ViacomCBS
$42.36 /

+0.845 (+2.04%)

T AT&T
$29.33 /

+0.15 (+0.51%)

SONY Sony
$99.64 /

+0.915 (+0.93%)

LGF.A Lionsgate
$20.28 /

-0.11 (-0.54%)

DIS Disney
$177.36 /

+0.81 (+0.46%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$56.88 /

+0.29 (+0.51%)

T AT&T
$29.33 /

+0.15 (+0.51%)

05/24/21 Morgan Stanley
AT&T price target lowered to $32 from $34 at Morgan Stanley
05/24/21 Benchmark
Benchmark does not 'attach any credence' to idea AT&T could buy Charter
05/24/21 MoffettNathanson
MoffettNathanson downgrades Discovery to Neutral after WarnerMedia deal news
05/24/21 MoffettNathanson
Discovery downgraded to Neutral from Buy at MoffettNathanson
CMCSA Comcast
$56.88 /

+0.29 (+0.51%)

05/24/21 HSBC
Comcast price target raised to $64 from $56 at HSBC
05/18/21 Benchmark
Comcast selloff on Discovery-WarnerMedia news 'excessive,' says Benchmark
05/17/21 Citi
Discovery upgraded to Buy from Neutral at Citi
05/04/21 Deutsche Bank
Comcast price target raised to $65 from $60 at Deutsche Bank
CMCSK Comcast
$58.00 /

+ (+0.00%)

02/23/21 Credit Suisse
SeaWorld price target raised to $52 from $34 at Credit Suisse
10/07/20 Benchmark
Benchmark would be 'aggressive buyer' of Comcast amid broader market weakness
09/22/20 Benchmark
Comcast price target raised to $60 from $54 at Benchmark
09/16/20 Pivotal Research
Comcast price target raised to $60 from $52 at Pivotal Research
SONY Sony
$99.64 /

+0.915 (+0.93%)

LGF.A Lionsgate
$20.28 /

-0.11 (-0.54%)

06/04/21 Barrington
Lionsgate price target raised to $27 from $16 at Barrington
06/01/21 Cowen
Lionsgate price target raised to $23 from $20 at Cowen
05/28/21 RBC Capital
Lionsgate price target raised to $17 from $13 at RBC Capital
05/26/21 Truist
Amazon's MGM deal 'a very modest negative' for Netflix/Disney, says Truist
LGF.B Lionsgate
$17.85 /

-0.2 (-1.11%)

05/26/21 Loop Capital
Lionsgate price target raised to $21 from $16 at Loop Capital
DIS Disney
$177.36 /

+0.81 (+0.46%)

06/10/21 Wolfe Research
Wolfe says Disney risk/reward 'compelling,' keeps $226 price target
05/26/21 Piper Sandler
Amazon deal to buy MGM Studios 'looks sensible,' says Piper Sandler
05/18/21 Morgan Stanley
Morgan Stanley says Amazon-MGM would be 'biggest signal yet' of streaming focus
VIACA ViacomCBS
$46.64 /

+0.6 (+1.30%)

01/05/21 Gabelli
ViacomCBS named a best idea for 2021 at Gabelli
07/13/20
Fly Intel: Top five analyst initiations
07/13/20
Fly Intel: Top five analyst downgrades
VIAC ViacomCBS
$42.36 /

+0.845 (+2.04%)

05/24/21 Truist
Lionsgate price target raised to $19 from $15 at Truist
05/21/21 Citi
ViacomCBS price target lowered to $54 from $56 at Citi
05/20/21
Fly Intel: Top five analyst upgrades
05/20/21 BofA
ViacomCBS upgraded to Buy from Underperform at BofA
VIACA ViacomCBS
$46.64 /

+0.6 (+1.30%)

VIAC ViacomCBS
$42.36 /

+0.845 (+2.04%)

T AT&T
$29.33 /

+0.15 (+0.51%)

SONY Sony
$99.64 /

+0.915 (+0.93%)

LGF.A Lionsgate
$20.28 /

-0.11 (-0.54%)

DIS Disney
$177.36 /

+0.81 (+0.46%)

CMCSA Comcast
$56.88 /

+0.29 (+0.51%)

  • 06
    Apr
  • 29
    Mar
  • 24
    Mar
VIACA ViacomCBS
$46.64 /

+0.6 (+1.30%)

VIAC ViacomCBS
$42.36 /

+0.845 (+2.04%)

T AT&T
$29.33 /

+0.15 (+0.51%)

SONY Sony
$99.64 /

+0.915 (+0.93%)

DIS Disney
$177.36 /

+0.81 (+0.46%)

CMCSA Comcast
$56.88 /

+0.29 (+0.51%)

VIACA ViacomCBS
$46.64 /

+0.6 (+1.30%)

T AT&T
$29.33 /

+0.15 (+0.51%)

SONY Sony
$99.64 /

+0.915 (+0.93%)

LGF.A Lionsgate
$20.28 /

-0.11 (-0.54%)

DIS Disney
$177.36 /

+0.81 (+0.46%)

CMCSA Comcast
$56.88 /

+0.29 (+0.51%)

VIAC ViacomCBS
$42.36 /

+0.845 (+2.04%)

T AT&T
$29.33 /

+0.15 (+0.51%)

SONY Sony
$99.64 /

+0.915 (+0.93%)

DIS Disney
$177.36 /

+0.81 (+0.46%)

CMCSA Comcast
$56.88 /

+0.29 (+0.51%)

Periodicals
J&J vaccine delivery to South Africa in limbo, Bloomberg reports » 17:35
06/13/21
06/13
17:35
06/13/21
17:35
JNJ

Johnson & Johnson

$164.99 /

-2.065 (-1.24%)

Johnson & Johnson…

Johnson & Johnson COVID-19 vaccines intended for South Africa remain suspended following a U.S. ruling that ingredients for the country's doses may have been contaminated during production in a plant in Baltimore, Bloomberg's John Bowker reports. The U.S. Food and Drug Administration said Friday that some batches of the J&J version were not fit to use, while others are still under review, the author notes, adding that two lots have been approved, though it's not clear where those are headed or how many that covers. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

06/08/21 Wedbush
Argenx price target lowered to $344 from $356 at Wedbush
06/08/21 Baird
Argenx price target lowered to $333 from $346 at Baird
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

Hot Stocks
Musk says Tesla will accept bitcoin payments when miners use more clean energy » 16:34
06/13/21
06/13
16:34
06/13/21
16:34
TSLA

Tesla

$609.92 /

-0.16 (-0.03%)

Tesla's CEO Elon…

Tesla's CEO Elon Musk said via Twitter that, "Tesla only sold ~10% of holdings to confirm BTC could be liquidated easily without moving market. When there's confirmation of reasonable (~50%) clean energy usage by miners with positive future trend, Tesla will resume allowing Bitcoin transactions."Reference Link

ShowHide Related Items >><<
TSLA Tesla
$609.92 /

-0.16 (-0.03%)

TSLA Tesla
$609.92 /

-0.16 (-0.03%)

06/11/21 Credit Suisse
Tesla's Model S Plaid reinforces brand DNA, says Credit Suisse
06/11/21 Goldman Sachs
Goldman says Tesla's Model S Plaid helps illustrate technology leadership
06/08/21 GLJ Research
Tesla's China orders down 69% in Q2 versus Q1, says GLJ Research
06/08/21 Wedbush
Tesla China numbers rebound in 'big way,' says Wedbush
TSLA Tesla
$609.92 /

-0.16 (-0.03%)

TSLA Tesla
$609.92 /

-0.16 (-0.03%)

TSLA Tesla
$609.92 /

-0.16 (-0.03%)

TSLA Tesla
$609.92 /

-0.16 (-0.03%)

Hot Stocks
Kite announces follow-up results from ZUMA-5 trial of Yescarta » 16:02
06/13/21
06/13
16:02
06/13/21
16:02
GILD

Gilead

$68.77 /

-0.54 (-0.78%)

Kite, a Gilead company,…

Kite, a Gilead company, announced follow-up results from the pivotal ZUMA-5 trial of Yescarta - the first and only CAR T-cell therapy approved in patients with relapsed or refractory indolent follicular lymphoma. At a minimum follow-up of 18 months, 94% of patients had achieved a response, and secondary endpoints of median progression-free survival and overall survival were not yet reached. In a weighted analysis comparing ZUMA-5 patients with a minimum of 18 months follow-up with those observed in SCHOLAR-5, an external control cohort, Yescarta demonstrated superior OS and PFS over currently available treatments. These data were presented as a part of a late-breaking session at the 26th Annual Meeting of the European Hematology Association taking place virtually this year from June 9-17. The propensity score analysis compared follow-up data from the pivotal Phase 2 ZUMA-5 study to a weighted sample from the SCHOLAR-5 external control cohort of current therapies, balanced for patient characteristics through propensity scoring. Ninety-four percent of patients in the ZUMA-5 cohort achieved a response compared to 50% of patients in the control cohort, with an odds ratio of 16.2. Yescarta demonstrated a 58% reduction in the risk of death and 70% reduction in the risk of disease progression, relapse or death versus current therapies in the control cohort. While median OS and PFS were both not reached in ZUMA-5, median PFS and OS were 12.7 months and 59.8 months, respectively, in the control cohort. In the ZUMA-5 safety analysis set, Grade 3 or higher cytokine release syndrome and neurologic toxicities occurred in 8% and 21% of patients, respectively. Yescarta received accelerated approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in March 2021. The Yescarta U.S. Prescribing Information has a BOXED WARNING for the risks of CRS and neurologic toxicities, and Yescarta is approved with a risk evaluation and mitigation strategy due to these risks; see below for Important Safety Information.

ShowHide Related Items >><<
GILD Gilead
$68.77 /

-0.54 (-0.78%)

GILD Gilead
$68.77 /

-0.54 (-0.78%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Bernstein
Gilead upgraded to Outperform from Market Perform at Bernstein
03/30/21 Redburn
Gilead upgraded to Buy from Neutral at Redburn
03/15/21 Mizuho
Merck's Gilead collaboration likely to broaden reach of islatravir, says Mizuho
GILD Gilead
$68.77 /

-0.54 (-0.78%)

GILD Gilead
$68.77 /

-0.54 (-0.78%)

GILD Gilead
$68.77 /

-0.54 (-0.78%)

GILD Gilead
$68.77 /

-0.54 (-0.78%)

Conference/Events
Harmonic to host virtual investor event » 15:18
06/13/21
06/13
15:18
06/13/21
15:18
HLIT

Harmonic

$7.59 /

+0.01 (+0.13%)

Virtual Investor Event to…

Virtual Investor Event to be held on June 14 at 1 pm. Webcast Link

ShowHide Related Items >><<
HLIT Harmonic
$7.59 /

+0.01 (+0.13%)

HLIT Harmonic
$7.59 /

+0.01 (+0.13%)

06/01/21 Jefferies
Nearly 10% of ARPA funds going to broadband, says Jefferies
02/02/21 Stifel
Harmonic price target raised to $10 after 'strong results' at Stifel
01/14/21 Barclays
Harmonic price target raised to $8 from $7 at Barclays
09/23/20 Colliers
Harmonic opportunity in focus after SES partners with Microsoft, says Colliers
HLIT Harmonic
$7.59 /

+0.01 (+0.13%)

HLIT Harmonic
$7.59 /

+0.01 (+0.13%)

Conference/Events
Gracell to host conference call » 15:02
06/13/21
06/13
15:02
06/13/21
15:02
GRCL

Gracell

$14.35 /

+0.11 (+0.77%)

Management holds a…

Management holds a clinical update conference call on June 14 at 8 am. Webcast Link

ShowHide Related Items >><<
GRCL Gracell
$14.35 /

+0.11 (+0.77%)

GRCL Gracell
$14.35 /

+0.11 (+0.77%)

06/07/21 Citi
Gracell valuation provides attractive entry point, says Citi
06/04/21 Piper Sandler
Piper sees 'clear line of sight for value creation' at Gracell after ASCO
04/30/21 Piper Sandler
Gracell transferred with Overweight rating at Piper Sandler
02/03/21 Citi
Gracell initiated with a Buy at Citi
GRCL Gracell
$14.35 /

+0.11 (+0.77%)

  • 08
    Jan
GRCL Gracell
$14.35 /

+0.11 (+0.77%)

Hot Stocks
AbbVie says Phase 3 GLOW study met primary endpoint of superior PFS » 11:51
06/13/21
06/13
11:51
06/13/21
11:51
ABBV

AbbVie

$115.42 /

-0.85 (-0.73%)

AbbVie announced new data…

AbbVie announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA plus VENCLEXTA/VENCLYXTO versus chlorambucil plus obinutuzumab for first-line treatment in patients with chronic lymphocytic leukemia, or CLL, or small lymphocytic lymphoma, or SLL, who had active disease requiring treatment per the International Workshop on CLL criteria. The study met its primary endpoint of superior progression-free survival, or PFS, as assessed by an independent review committee with a HR 0.216, demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. I+V is the first all-oral, once-daily, chemotherapy-free, fixed-duration investigational combination, the company said. Results of the study will be presented at the European Hematology Association 2021 Virtual Congress during late-breaking abstract session on June 12. The PFS benefit with I+V was consistent across pre-specified subgroups, including patients 65 years and older and those with comorbidities. The median PFS for C+O was 21 months while the median PFS for I+V had not been reached at the time of analysis. The safety profile of I+V was generally consistent with the safety profile of the single agents and tolerability profiles were consistent with CLL treatment in the enrolled patient population. Arnon Kater, M.D., Ph.D., deputy head of hematology, University of Amsterdam Faculty of Medicine, said, "The progression-free survival findings of ibrutinib and venetoclax in the GLOW study are promising and show the potential to become an additional treatment option for people living with CLL."

ShowHide Related Items >><<
ABBV AbbVie
$115.42 /

-0.85 (-0.73%)

ABBV AbbVie
$115.42 /

-0.85 (-0.73%)

05/19/21 Piper Sandler
Piper 'incrementally bullish' on Biohaven, AbbVie migraine drugs
05/13/21 Cantor Fitzgerald
Soliton downgraded to Neutral from Overweight at Cantor Fitzgerald
05/11/21 Maxim
Soliton downgraded to Hold from Buy at Maxim
05/03/21 Mizuho
AbbVie price target raised to $128 from $126 at Mizuho
ABBV AbbVie
$115.42 /

-0.85 (-0.73%)

ABBV AbbVie
$115.42 /

-0.85 (-0.73%)

ABBV AbbVie
$115.42 /

-0.85 (-0.73%)

ABBV AbbVie
$115.42 /

-0.85 (-0.73%)

Hot Stocks
Johnson & Johnson announces overall survival results from Phase 3 MAIA study » 11:48
06/13/21
06/13
11:48
06/13/21
11:48
JNJ

Johnson & Johnson

$164.99 /

-2.065 (-1.24%)

The Janssen…

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival, or OS, results from the Phase 3 MAIA study showing the addition of Darzalex to lenalidomide and dexamethasone, or D-Rd, resulted in a statistically significant survival benefit over lenalidomide and dexamethasone, or Rd, alone in patients with newly diagnosed multiple myeloma who were ineligible for autologous stem cell transplant and were treated to progression. The prespecified interim analysis for OS found that after a median follow-up of nearly five years, a 32% reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm. Median OS was not reached in either arm. Median progression-free survival, or PFS, was not reached after nearly five years and the PFS benefit observed with D-Rd was maintained, with a 47% reduction in risk of disease progression or death. These data, which were featured in the European Hematology Association 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress, are expected to form the basis of future regulatory submissions. Thierry Facon, M.D., Professor of Haematology at Lille University Hospital, Lille, France and study investigator, said, "These results strongly support the use of daratumumab, lenalidomide and dexamethasone as a new standard of care to extend survival and improve clinical outcomes in transplant ineligible patients with newly diagnosed multiple myeloma."

ShowHide Related Items >><<
JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

06/08/21 Wedbush
Argenx price target lowered to $344 from $356 at Wedbush
06/08/21 Baird
Argenx price target lowered to $333 from $346 at Baird
06/07/21 BofA
BofA upgrades Biogen to Neutral with $400 price target after Aduhelm approved
06/02/21 Jefferies
Legend Biotech cilta-cel PFS rate 'largely exceeds' expectation, says Jefferies
JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

JNJ Johnson & Johnson
$164.99 /

-2.065 (-1.24%)

On The Fly
On the Fly: The Week in SPAC News » 09:42
06/13/21
06/13
09:42
06/13/21
09:42
ZNTE

Zanite Acquisition

$10.11 /

+0.01 (+0.10%)

, ERJ

Embraer

$16.35 /

+0.63 (+4.01%)

, BSN

Broadstone Acquisition

$9.97 /

+0.05 (+0.50%)

, RYCEY

Rolls-Royce

$1.63 /

+0.02 (+1.24%)

, MSFT

Microsoft

$257.88 /

+0.64 (+0.25%)

, AAL

American Airlines

$23.54 /

+0.075 (+0.32%)

, HON

Honeywell

$225.11 /

-1.19 (-0.53%)

, EVTL

Vertical Aerospace

/

+

, TMTS

Spartacus Acquisition

$10.05 /

-0.01 (-0.10%)

, NN

NextNav

/

+

, KVSA

Khosla Ventures Acquisition

$9.90 /

-0.01 (-0.10%)

, VPCC

VPC Impact Acquisition Holdings III

$9.94 /

+0.03 (+0.30%)

, NBR

Nabors Industries

$117.35 /

+4.91 (+4.37%)

, BMWYY

BMW

$38.33 /

+0.545 (+1.44%)

, F

Ford

$15.28 /

+0.17 (+1.13%)

, DCRC

Decarbonization Plus Acquisition III

$12.39 /

+1.47 (+13.46%)

, AMZN

Amazon.com

$3,346.75 /

-3.33 (-0.10%)

, CCV

Churchill Capital Corp V

$10.26 /

+0.25 (+2.50%)

, HZON

Horizon Acquisition Corp. II

$9.78 /

+0.01 (+0.10%)

, FAII

Fortress Value Acquisition Corp. II

$10.13 /

+0.155 (+1.55%)

, NBA

New Beginnings Acquisition

$10.02 /

-0.03 (-0.30%)

, GIX

GigCapital2

/

+

, UPH

UpHealth

$8.94 /

-1.04 (-10.42%)

, FRX

Forest Road Acquisition

$10.35 /

+0.03 (+0.29%)

, NSH

NavSight Holdings

$10.01 /

+0.045 (+0.45%)

, NGAC

NextGen Acquisition Corp.

$10.00 /

+0.03 (+0.30%)

, LITT

Logistics Innovation Technologies

/

+

, LAAA

Lakeshore Acquisition I

/

+

, BSGA

Blue Safari Group Acquisition

/

+

, SMIH

Summit Healthcare Acquisition

/

+

, ISAA

Iron Spark I

$9.96 /

+0.01 (+0.10%)

, GACQ

Global Consumer Acquisition

/

+

, CLBR

Colombier Acquisition

/

+

, DAVE

Famous Dave's

$4.68 /

+ (+0.00%)

In SPAC news this week,…

ShowHide Related Items >><<
ZNTE Zanite Acquisition
$10.11 /

+0.01 (+0.10%)

VPCC VPC Impact Acquisition Holdings III
$9.94 /

+0.03 (+0.30%)

TMTS Spartacus Acquisition
$10.05 /

-0.01 (-0.10%)

RYCEY Rolls-Royce
$1.63 /

+0.02 (+1.24%)

NSH NavSight Holdings
$10.01 /

+0.045 (+0.45%)

NGAC NextGen Acquisition Corp.
$10.00 /

+0.03 (+0.30%)

NBR Nabors Industries
$117.35 /

+4.91 (+4.37%)

NBA New Beginnings Acquisition
$10.02 /

-0.03 (-0.30%)

MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

KVSA Khosla Ventures Acquisition
$9.90 /

-0.01 (-0.10%)

HZON Horizon Acquisition Corp. II
$9.78 /

+0.01 (+0.10%)

HON Honeywell
$225.11 /

-1.19 (-0.53%)

GIX GigCapital2
/

+

FRX Forest Road Acquisition
$10.35 /

+0.03 (+0.29%)

FAII Fortress Value Acquisition Corp. II
$10.13 /

+0.155 (+1.55%)

F Ford
$15.28 /

+0.17 (+1.13%)

ERJ Embraer
$16.35 /

+0.63 (+4.01%)

BSN Broadstone Acquisition
$9.97 /

+0.05 (+0.50%)

BMWYY BMW
$38.33 /

+0.545 (+1.44%)

AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

AAL American Airlines
$23.54 /

+0.075 (+0.32%)

ZNTE Zanite Acquisition
$10.11 /

+0.01 (+0.10%)

ERJ Embraer
$16.35 /

+0.63 (+4.01%)

06/11/21 BofA
Embraer upgraded to Buy at BofA on 'significant' eVTOL opportunity
06/11/21 BofA
Embraer upgraded to Buy from Neutral at BofA
03/23/21 JPMorgan
Embraer price target raised to $13.50 from $9.50 at JPMorgan
08/11/20
Fly Intel: Top five analyst downgrades
BSN Broadstone Acquisition
$9.97 /

+0.05 (+0.50%)

RYCEY Rolls-Royce
$1.63 /

+0.02 (+1.24%)

03/23/21 UBS
Rolls-Royce price target raised to 119 GBp from 111 GBp at UBS
03/17/21 Berenberg
Rolls-Royce price target raised to 150 GBp from 130 GBp at Berenberg
03/16/21 JPMorgan
Rolls-Royce upgraded to Neutral from Underweight at JPMorgan
03/16/21 JPMorgan
Rolls-Royce upgraded to Neutral from Underweight at JPMorgan
MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

06/07/21 Morgan Stanley
Microsoft valuation presents 'attractive entry point,' says Morgan Stanley
06/03/21 Tigress Financial
Microsoft shares going to $303 in 12 months, says Tigress Financial
06/01/21 KGI Securities
Microsoft initiated with an Outperform at KGI Securities
05/27/21 UBS
Zoom Video initiated with a Neutral at UBS
AAL American Airlines
$23.54 /

+0.075 (+0.32%)

06/09/21 MKM Partners
American Airlines initiated with a Buy at MKM Partners
06/09/21 MKM Partners
American Airlines initiated with a Buy at MKM Partners
04/23/21 Raymond James
American Airlines upgraded to Market Perform from Underperform at Raymond James
04/23/21 Raymond James
American Airlines upgraded to Market Perform from Underperform at Raymond James
HON Honeywell
$225.11 /

-1.19 (-0.53%)

05/21/21 JPMorgan
Honeywell growth opportunities underappreciated, says JPMorgan's Tusa
04/26/21 Credit Suisse
Honeywell price target raised to $235 from $224 at Credit Suisse
04/26/21 Barclays
Honeywell price target raised to $245 from $230 at Barclays
04/26/21 Baird
Honeywell pullback a buying opportunity, says Baird
EVTL Vertical Aerospace
/

+

TMTS Spartacus Acquisition
$10.05 /

-0.01 (-0.10%)

NN NextNav
/

+

KVSA Khosla Ventures Acquisition
$9.90 /

-0.01 (-0.10%)

VPCC VPC Impact Acquisition Holdings III
$9.94 /

+0.03 (+0.30%)

NBR Nabors Industries
$117.35 /

+4.91 (+4.37%)

08/18/20 Citi
Nabors Industries downgraded to Sell from Neutral at Citi
08/12/20 Goldman Sachs
Nabors Industries downgraded to Sell from Neutral at Goldman Sachs
08/03/20 Barclays
Barclays upgrades Nabors to Equal Weight on improved earnings outlook
08/03/20 Barclays
Nabors Industries upgraded to Equal Weight from Underweight at Barclays
BMWYY BMW
$38.33 /

+0.545 (+1.44%)

06/10/21 Stifel
BMW downgraded to Hold from Buy at Stifel
06/07/21 JPMorgan
BMW price target raised to EUR 95 from EUR 90 at JPMorgan
05/20/21 RBC Capital
BMW price target raised to EUR 92 from EUR 87 at RBC Capital
05/17/21 Barclays
BMW price target raised to EUR 95 from EUR 83 at Barclays
F Ford
$15.28 /

+0.17 (+1.13%)

06/04/21 JPMorgan
Ford price target raised to $18 from $16 at JPMorgan
05/28/21 Deutsche Bank
Deutsche starts Lordstown with Hold on 'considerable uncertainty'
05/27/21
Fly Intel: Top five analyst upgrades
05/27/21 Jefferies
Ford 'playing to its strengths' with new EV strategy, says Jefferies
DCRC Decarbonization Plus Acquisition III
$12.39 /

+1.47 (+13.46%)

AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

06/08/21 Piper Sandler
New Amazon offering targets Hims & Hers and others, says Piper Sandler
06/08/21 UBS
Snowflake price target raised to $300 from $275 at UBS
06/07/21 Loop Capital
Best Buy prices remain 'very competitive' to Amazon's, says Loop Capital
06/07/21 Roth Capital
iPower initiated with a Buy at Roth Capital
CCV Churchill Capital Corp V
$10.26 /

+0.25 (+2.50%)

HZON Horizon Acquisition Corp. II
$9.78 /

+0.01 (+0.10%)

FAII Fortress Value Acquisition Corp. II
$10.13 /

+0.155 (+1.55%)

06/09/21 Barrington
Fortress Value Acquisition Corp. II initiated with an Outperform at Barrington
05/04/21 Benchmark
Fortress Value Acquisition Corp. II initiated with a Buy at Benchmark
NBA New Beginnings Acquisition
$10.02 /

-0.03 (-0.30%)

06/09/21 DA Davidson
Airspan Networks initiated with a Buy at DA Davidson
04/08/21
Fly Intel: Top five analyst initiations
04/08/21 Barrington
New Beginnings Acquisition initiated with an Outperform at Barrington
GIX GigCapital2
/

+

06/08/21 Colliers
Colliers starts UpHealth SPAC partner GigCapital2 at Buy with $14 price target
06/08/21 Colliers
GigCapital2 initiated with a Buy at Colliers
04/16/21 Benchmark
GigCapital2 initiated with a Buy at Benchmark
UPH UpHealth
$8.94 /

-1.04 (-10.42%)

FRX Forest Road Acquisition
$10.35 /

+0.03 (+0.29%)

06/07/21 Loop Capital
Forest Road Acquisition initiated with a Hold at Loop Capital
NSH NavSight Holdings
$10.01 /

+0.045 (+0.45%)

06/11/21 Benchmark
NavSight Holdings initiated with a Buy at Benchmark
NGAC NextGen Acquisition Corp.
$10.00 /

+0.03 (+0.30%)

06/11/21 Benchmark
NextGen Acquisition Corp. initiated with a Buy at Benchmark
LITT Logistics Innovation Technologies
/

+

LAAA Lakeshore Acquisition I
/

+

BSGA Blue Safari Group Acquisition
/

+

SMIH Summit Healthcare Acquisition
/

+

ISAA Iron Spark I
$9.96 /

+0.01 (+0.10%)

GACQ Global Consumer Acquisition
/

+

CLBR Colombier Acquisition
/

+

DAVE Famous Dave's
$4.68 /

+ (+0.00%)

NBR Nabors Industries
$117.35 /

+4.91 (+4.37%)

MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

HON Honeywell
$225.11 /

-1.19 (-0.53%)

F Ford
$15.28 /

+0.17 (+1.13%)

ERJ Embraer
$16.35 /

+0.63 (+4.01%)

BMWYY BMW
$38.33 /

+0.545 (+1.44%)

AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

AAL American Airlines
$23.54 /

+0.075 (+0.32%)

  • 10
    Nov
  • 15
    Oct
  • 23
    Jun
RYCEY Rolls-Royce
$1.63 /

+0.02 (+1.24%)

MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

HZON Horizon Acquisition Corp. II
$9.78 /

+0.01 (+0.10%)

F Ford
$15.28 /

+0.17 (+1.13%)

DCRC Decarbonization Plus Acquisition III
$12.39 /

+1.47 (+13.46%)

CCV Churchill Capital Corp V
$10.26 /

+0.25 (+2.50%)

BMWYY BMW
$38.33 /

+0.545 (+1.44%)

AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

AAL American Airlines
$23.54 /

+0.075 (+0.32%)

ZNTE Zanite Acquisition
$10.11 /

+0.01 (+0.10%)

NBR Nabors Industries
$117.35 /

+4.91 (+4.37%)

NBA New Beginnings Acquisition
$10.02 /

-0.03 (-0.30%)

MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

KVSA Khosla Ventures Acquisition
$9.90 /

-0.01 (-0.10%)

HZON Horizon Acquisition Corp. II
$9.78 /

+0.01 (+0.10%)

HON Honeywell
$225.11 /

-1.19 (-0.53%)

FAII Fortress Value Acquisition Corp. II
$10.13 /

+0.155 (+1.55%)

F Ford
$15.28 /

+0.17 (+1.13%)

ERJ Embraer
$16.35 /

+0.63 (+4.01%)

CCV Churchill Capital Corp V
$10.26 /

+0.25 (+2.50%)

BMWYY BMW
$38.33 /

+0.545 (+1.44%)

AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

AAL American Airlines
$23.54 /

+0.075 (+0.32%)

ZNTE Zanite Acquisition
$10.11 /

+0.01 (+0.10%)

NSH NavSight Holdings
$10.01 /

+0.045 (+0.45%)

NGAC NextGen Acquisition Corp.
$10.00 /

+0.03 (+0.30%)

MSFT Microsoft
$257.88 /

+0.64 (+0.25%)

HZON Horizon Acquisition Corp. II
$9.78 /

+0.01 (+0.10%)

HON Honeywell
$225.11 /

-1.19 (-0.53%)

GIX GigCapital2
/

+

FRX Forest Road Acquisition
$10.35 /

+0.03 (+0.29%)

FAII Fortress Value Acquisition Corp. II
$10.13 /

+0.155 (+1.55%)

F Ford
$15.28 /

+0.17 (+1.13%)

ERJ Embraer
$16.35 /

+0.63 (+4.01%)

CCV Churchill Capital Corp V
$10.26 /

+0.25 (+2.50%)

AMZN Amazon.com
$3,346.75 /

-3.33 (-0.10%)

AAL American Airlines
$23.54 /

+0.075 (+0.32%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.